Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

altRX vs Midi Health

altRX
Graded #92

Higher grade

vs+15.000000000000007
Midi Health
Graded #413

Lower grade

The verdict

altRX takes it — 71.4/100 to 56.4/100.

altRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. altRX is a dual-modality telehealth platform offering compounded GLP-1s plus all four brand-name FDA-approved options — Mounjaro, Ozempic, Wegovy, and Zepbound — the most comprehensive brand-name lineup in…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuealtRX +29
74
45
Dose & formulationaltRX +37
77
40
Clinical oversightaltRX +4
82
78
Labs & monitoringaltRX +1
53
52
FulfillmentMidi Health +5
73
78
Contract termsEven
55
55
altRX · left barMidi Health · right bar

The numbers

MetricaltRXMidi Health
WeighScore71.4/10056.4/100
GradeCC
Scorecard rank#92#413
Semaglutide$149/mo (starting dose, compounded)Not disclosed
Tirzepatide$249/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
altRX

Graded #92 · C

Strengths

  • Offers all four brand-name FDA-approved GLP-1s (Mounjaro, Ozempic, Wegovy, Zepbound) — the most comprehensive brand-name access we've reviewed
  • LegitScript Certified with a publicly verifiable seal
  • Publishes the FDA compounded-medication disclaimer
  • Transparent pricing across all six product tiers (compounded plus four brand-name)
  • All-inclusive pricing — consult, prescription, and shipping with no hidden fees

Where it loses points

  • States-served list not disclosed
  • 503A/503B pharmacy partner not named (only 'multiple USA-certified pharmacies')
  • 503A vs 503B designation not specified
  • No named medical director
  • Corporate physical address not disclosed
Midi Health

Graded #413 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard